Phase 1 Study of BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Description

This is a Phase 1, open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of BLU-667 administered orally in patients with NSCLC, thyroid cancer and other solid tumors.

Study Start Date

March, 17 2017

Estimated Completion Date

March 2023

Interventions

  • Drug: BLU-667

Study ID

Blueprint Medicines Corporation -- BLU-667-1101

Status

Recruiting

Trial ID

NCT03037385

Study Type

Interventional

Trial Phase

Phase 1

Enrollment Quota

115

Sponsor

Blueprint Medicines Corporation

Key

Inclusion Criteria

  • Diagnosis during dose escalation (Part 1)
  • Pathologically documented, definitively diagnosed non-resectable advanced solid tumor.
  • All patients treated at doses > 120 mg per day must have medullary thyroid cancer (MTC), or a RET-altered solid tumor per local assessment of tumor tissue and/or blood.
  • Diagnosis during dose expansion (Part 2)
  • All patients in Groups 1, 2 and 4 must have a RET-altered (excluding synonymous and nonsense mutations) solid tumor, as determined by local testing of tumor or circulating tumor nucleic acid in blood
  • as detailed below.
  • Group 1
  • patients must have pathologically documented, definitively diagnosed locally advanced or metastatic NSCLC with a RET rearrangement that was previously treated with a tyrosine kinase inhibitor (TKI) that inhibits RET, such as cabozantinib, vandetanib, ponatinib, sorafenib and alectinib.
  • Group 2
  • patients must have pathologically documented, definitively diagnosed locally advanced or metastatic NSCLC with a RET rearrangement that was not previously treated with a TKI that inhibits RET.
  • Group 3
  • patients must have pathologically documented, definitively diagnosed advanced MTC that has progressed within 14 months prior to the Screening Visit.
  • Group 4
  • patients must have a pathologically documented, definitively diagnosed advanced solid tumor with a RET alteration, other than NSCLC and MTC.
  • Patient must have non-resectable disease that has progressed following standard therapy or has not adequately responded to standard therapy, or the patient must be intolerant to or have declined available standard therapies, or there must be no accepted standard therapy for their disease.
  • Patient has Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2. Key

Exclusion Criteria

  • Patient has NSCLC with a targetable mutation in EGFR, ALK, or ROS1.
  • Patient has any of the following within 14 days prior to the first dose of study drug: 1. Platelet count < 75 × 10^9/L. 2. Absolute neutrophil count <1.0 × 10^9/L. 3. Hemoglobin < 9.0 g/dL (red blood cell transfusion and erythropoietin may be used to reach at least 9.0 g/dL, but must have been administered at least 2 weeks prior to the first dose of study drug. 4. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 × the upper limit of normal (ULN) if no hepatic metastases are present
  • >5 × ULN if hepatic metastases are present. 5. Total bilirubin > 1.5 × ULN > 3 × ULN with direct bilirubin > 1.5 × ULN in presence of Gilbert's disease. 6. Estimated (Cockcroft-Gault formula) or measured creatinine clearance <40 mL/min.
  • QT interval corrected using Fridericia's formula (QTcF) >470 msec or history of prolonged QT syndrome or Torsades de pointes, or familial history of prolonged QT syndrome.
  • Clinically significant, uncontrolled, cardiovascular disease.
  • Central nervous system (CNS) metastases or a primary CNS tumor that is associated with progressive neurological symptoms.

Gender

All

Ages

18 Years and older

Accepts Healthy Volunteers

No

Study Locations and Contact Information (7)

Study Location Distance Name Phone Email
Dana Farber Cancer Center - Boston, Massachusetts 2.4 miles None None None
Massachusetts General Hospital - Boston, Massachusetts 2.8 miles None None None
University of Pennsylvania - Philadelphia, Pennsylvania 270.8 miles None None None
Duke University Medical Center - Durham, North Carolina 609.0 miles None None None
MD Anderson Cancer Center - Houston, Texas 1,609.9 miles None None None
Oregon Health and Science University - Portland, Oregon 2,538.3 miles None None None
UC Irvine Medical Center - Orange, California 2,585.0 miles None None None

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.